Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 4/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.36 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541082 | 1.00 | CYP3A4 (0.47) | CYP3A4TDP1ESR1ESR2CALM1 | |
| Hydrochloric Acid SCHEMBL8488594 | 0.97 | CYP3A4 (0.45) | CYP3A4TDP1ESR1ESR2CALM1 | |
| SCHEMBL27343 | 0.97 | CYP3A4 (0.50) | CYP3A4TDP1ESR1ESR2CALM1 | |
| SCHEMBL1705969 | 0.94 | CYP3A4 (0.47) | CYP3A4TDP1ESR1ESR2CALM1 | |
| SCHEMBL22749137 | 0.94 | CYP3A4 (0.47) | CYP3A4TDP1ESR1ESR2CALM1 | |
| Phosphine SCHEMBL25423478 | 0.94 | CYP3A4 (0.47) | CYP3A4TDP1ESR1ESR2CALM1 | |
| SCHEMBL9803491 | 0.94 | CYP3A4 (0.47) | CYP3A4TDP1ESR1ESR2CALM1 | |
| SCHEMBL8850573 | 0.94 | CYP3A4 (0.47) | CYP3A4TDP1ESR1ESR2CALM1 | |
| SCHEMBL5075553 | 0.94 | CYP3A4 (0.47) | CYP3A4TDP1ESR1ESR2CALM1 | |
| SCHEMBL5075524 | 0.94 | CYP3A4 (0.47) | CYP3A4TDP1ESR1ESR2CALM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472969-A1 | PROCESS FOR THE SYNTHESIS OF PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | Novartis AG (CH) | 2024-12-11 | — | — | EP | claimed |
| CN-118063294-A | Efficient preparation method of dapagliflozin intermediate | 山东新时代药业有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-117881670-A | Methods of making EGFR inhibitors | 缆图药品公司 | 2024-04-12 | — | — | CN | claimed |
| CN-115626929-B | Chiral bridged ring compounds with nitrogen atom as bridgehead carbon and synthesis method thereof | 苏州凯若利新材料科技有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-117510303-A | Synthesis method of monofluoro 1, 4-eneyne compound | 常州大学 | 2024-02-06 | — | — | CN | claimed |
| CN-117263861-A | Anti-tumor active molecule benzo [ b ] azepine derivative and synthetic method and application thereof | 常州大学 | 2023-12-22 | — | — | CN | claimed |
| EP-4267591-A2 | ORGANOMETALLIC COMPOUNDS | Umicore AG & Co. KG (DE) | 2023-11-01 | — | — | EP | claimed |
| CN-111132981-B | Process for preparing pyrido [1,2-A ] pyrimidin-4-one derivatives | 豪夫迈·罗氏有限公司 | 2023-10-31 | — | — | CN | claimed |
| CN-116802187-A | Organometallic compounds | 优米科尔股份公司及两合公司 | 2023-09-22 | — | — | CN | claimed |
| WO-2023143605-A1 | PROCESS FOR THE SYNTHESIS OF PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2023-08-03 | — | — | WO | claimed |
| US-8945244-B2 | Method and composition for improving fuel combustion | CARROLL & ASSOCIATES LLC | 2015-02-03 | — | — | US | claimed |
| WO-2014171931-A1 | GRAPHENE NANORIBBONS AS SEMICONDUCTORS | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-10-23 | — | — | WO | claimed |
| US-7503944-B2 | Method and composition for improving fuel combustion | CARROLL & ASSOCIATES LLC | 2009-03-17 | — | — | US | claimed |
| US-20070179294-A1 | Multicore indazolinone library | THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2007-08-02 | — | — | US | claimed |
| EP-1078931-B1 | Process for the preparation of vitamin D analogues | HOFFMANN LA ROCHE (CH) | 2006-03-08 | — | — | EP | claimed |
| EP-1239717-A2 | Electromagnetic shielding plate and method for producing the same | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2002-09-11 | — | — | EP | claimed |
| US-6294688-B1 | REACTING HYDROXY-PROTECTED EPOXIDE WITH FLUORINATED ALCOHOL IN PRESENCE OF PALLADIUM CATALYST TO PRODUCE ALCOHOL HAVING SAME STEREOCHEMISTRY AS STARTING MATERIAL | HOFFMAN-LA ROCHE INC. | 2001-09-25 | — | — | US | claimed |
| US-6291694-B1 | REACTING EPOXY-UNSATURATED ESTER COMPOUND WITH FLUORINATED ALCOHOL IN PRESENCE OF PALLADIUM CATALYST TO PRODUCE VITAMIN D ANALOG COMPOUND | HOFFMAN-LA ROCHE INC. | 2001-09-18 | — | — | US | claimed |
| EP-1078931-A2 | Process for the preparation of vitamin D analogues | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-28 | — | — | EP | claimed |
| EP-0741693-B1 | PROCESS FOR THE PREPARATION OF ARYLACETIC ESTER DERIVATIVES VIA PALLADIUM-CATALYZED CROSS COUPLING REACTION | NOVARTIS AG (CH) | 1999-03-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179294-A1 | Multicore indazolinone library | IPMK, TTK, IWS1 | CYP3A4 683/4885TDP1 2701/4885ESR1 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.